The diagnostics and life sciences tools sector is attracting continued investor interest across both private equity and large corporates, although the nature of that opportunity is evolving. There has been a clear expansion beyond oncology-centric diagnostics towards a broader spectrum of diagnostic technologies, such as specialty and advanced proteomics, immune monitoring, and increasingly consumer facing testing. Value is being seen in platforms that generate deeper biological insight and scale across multiple use cases.
Read the full article: M&A Trends in Diagnostics and Life Sciences Tools //
Source: https://pharmaphorum.com/sales-marketing/ma-trends-diagnostics-and-life-sciences-tools